WASHINGTON – A booster dose of the vaccine Pfizer against COVID-19 in children aged five to 11 increased the level of antibodies, as confirmed by the pharmaceutical company on Thursday, which also announced that it will request authorization for its use from the Food and Drug Administration (FDA for its acronym in English).
The additional dose, given six months after the first two doses, increased antibodies against the original strain of coronavirus six-fold.
The vaccine booster trials included 140 children aged five to 11 years. In a smaller analysis of 30 children in the trial, Pfizer said the extra dose increased the level of antibodies against the Omicron variant of the coronavirus by 36 percent.
This article was published in NBC News. To read it in full, Click here.
–
